Glicksman RM, Loblaw A, Morton G, Vesprini D, et al. Randomized trial of concomitant hypofractionated IMRT boost versus conventional fractionated IMRT boost for localized high-risk prostate cancer (pHART2-RCT). Int J Radiat Oncol Biol Phys 2023 Nov 16:S0360-3016(23)08131.
PMID: 37979707